卵巢肿瘤细胞体外药物敏感试验临床应用价值  

Clinical value of drug sensitivity test of ovarian tumor cells in vitro

作　　者：张金波[1] 肖雁冰[1] 王玉莹[1] 王少军[1] 

机构地区：[1]遵义医学院附属医院妇产科,贵州遵义563099

出　　处：《遵义医学院学报》2012年第6期507-509,共3页Journal of Zunyi Medical University

摘　　要：目的探讨三磷酸腺苷—肿瘤体外药敏检测在指导晚期卵巢上皮癌患者化疗中的临床应用价值。方法回顾性分析我科住院的晚期卵巢上皮癌20例患者病历,根据药敏实验结果选取敏感化疗方案9例为实验组,采取卵巢上皮癌化疗的一线化疗方案(铂类+紫杉醇)化疗者11例为对照组,比较两组近期临床疗效。结果实验组临床近期疗效好于对照组(Z=-3.636,P<0.001)。结论三磷酸腺苷-肿瘤体外药敏检测结果指导临床化疗与患者的临床近期疗效有很好的相关性,对指导晚期卵巢上皮癌个体化化疗有的临床价值。Objective To explore the clinical value of adenosine triphosphate - tumor chemosensitivity assay （ATP -TCA） in the guidance of the advanced epithelial ovarian carcinoma patients treated with chemotherapy. Methods Twenty cases of the advanced epithelial ovarian carcinoma at the Department of Gynecology in the Affiliated Hospital of Zunyi Medical College were analyzed retrospectively. This study was divided into the control group including 11 cases treated with the first -line chemotherapy （plati- num and paclitaxel） and the experiment group including 9 cases treated with sensitive chemotherapeutic program. The short - term clinical effects of these 2 groups were compared. Results The short - term clinical effects in the experiment group were better than those in the control group （ Z = - 3. 636, P 〈 0. 001 ）. Conclusion ATP- TCA -guided chemotherapy is significantly correlated with the short -term clinical effects and ATP - TCA might play an important role in the guidance of individualized chemother- apy for the advanced epithelial ovarian carcinoma.

关 键 词：卵巢上皮癌 三磷酸腺苷-肿瘤体外药敏检测 化疗 

分 类 号：R737.31[医药卫生—肿瘤]